Bionano Genomics, Inc. revenue by segment BNGO

Annual Quarterly

Bionano Genomics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $26.7 million, 94% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
Revenue
30
29
31
36
28
18
9
10
12
Product
28
+8.6%
share 93.5%
27
-1.0%
share 93.8%
27
+1.1%
share 87.8%
27
+30.9%
share 74.0%
20
share 73.5%
—
—
—
—
Product And Service Other
2
+35.9%
share 6.5%
2
-53.2%
share 6.2%
4
-59.9%
share 12.2%
9
+27.3%
share 26.0%
7
+17.4%
share 26.5%
6
+176.6%
share 35.0%
2
share 26.7%
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
BNGO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1411690
Former names
BioNano Genomics, Inc (until Oct 20, 2021); Bionano Genomics, Inc (until Oct 20, 2021); BioNanomatrix Inc (until Mar 24, 2011)

Other Laboratory Analytical Instruments companies

All 25 Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.